New combo treatment tested to shrink tough esophageal tumors before surgery
NCT ID NCT07283991
Summary
This study is testing if adding an immunotherapy drug called QL1706 to standard chemotherapy can help shrink tumors in people with a hard-to-treat form of esophageal cancer. The goal is to make surgery more successful. About 24 participants in China will receive the drug combination before surgery, followed by ongoing maintenance therapy with QL1706.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.